Context Therapeutics Stock Math Transform Inverse Tangent Over Price Movement

CNTX Stock  USD 3.36  0.27  8.74%   
The math transform view organizes Inverse Tangent Over Price Movement transformation and supporting indicators around Context Therapeutics. The analysis highlights price transformations that reveal shifts in trend structure and frames technical signals with volatility and risk context.

Transformation
The output start index for this execution was zero with a total number of output elements of sixty-one. Context Therapeutics Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Context Therapeutics price patterns.

Context Therapeutics Technical Analysis Modules

Most technical analysis of Context Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Context from various momentum indicators to cycle indicators. When you analyze Context charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

Stock Overview, Methodology & Data Sources

The stock is undergoing an active upward rally.Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. Context Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. Downside history and drawdown behavior provide context for risk expectations in Context Therapeutics. Past price movements indicate comparatively limited downside dispersion. Context Therapeutics has a market cap of 308.71 M, ROE of -33.68%.

Methodology

Unless otherwise specified, financial data for Context Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Context (USA Stocks:CNTX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Context Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR. Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Context Therapeutics is covered by 10 analysts. 5 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Jefferies, Raymond James, Goldman Sachs, Bank of America Securities, Morgan Stanley, Deutsche Bank, Wells Fargo Securities, among others. Updates may occur throughout the day.

This content is curated and reviewed by:

Raphi Shpitalnik - Junior Member of Macroaxis Editorial Board

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Context Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Context Therapeutics' short interest history, or implied volatility extrapolated from Context Therapeutics options trading.

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Macroaxis Picks Idea
Macroaxis Picks
Invested few shares
Baby Boomer Prospects Idea
Baby Boomer Prospects
Invested over 20 shares
Macroaxis Index Idea
Macroaxis Index
Invested over 60 shares
Investor Favorites Idea
Investor Favorites
Invested few shares
Momentum Idea
Momentum
Invested few shares
Hedge Favorites Idea
Hedge Favorites
Invested few shares
Corona Opportunity Idea
Corona Opportunity
Invested few shares
Advertising Idea
Advertising
Invested few shares
Blockchain Idea
Blockchain
Invested few shares
Warren Buffett Holdings Idea
Warren Buffett Holdings
Invested over 20 shares
Cash Cows Idea
Cash Cows
Invested few shares

More Resources for Context Stock Analysis

A structured review of Context Therapeutics often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Context Therapeutics Stock. Highlighted below are reports that provide context for Context Therapeutics Stock:
Context Therapeutics has a market cap of 308.71 M, ROE of -33.68%. Trending Equities can help frame allocation decisions. The allocation includes a position in Context Therapeutics inside the allocation mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Explore our How to Trade Context Stock guide to learn how to trade Context Therapeutics effectively.
Analysis related to Context Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
 Earnings Share
-0.24
 Return On Assets
-0.23
 Return On Equity
-0.34
Market capitalization and book value offer complementary views of Context Therapeutics — the first driven by investor sentiment, the second by accounting standards. Context Therapeutics' market capitalization is 308.71 M. With a P/B ratio of 4.23, the market values Context Therapeutics well above its book equity. Enterprise value stands at 232.38 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Value and price for Context Therapeutics are related but not identical, and they can diverge across cycles. For Context Therapeutics, key inputs include a P/B ratio of 4.23, and ROE of -33.68%. By contrast, market price reflects the level where buyers and sellers transact.